Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis

References

• Sambala EZ, Ngcobo N, Machingaidze S, Wiyeh AB. A global review of seasonal influenza vaccine introduction: analysis of the WHO/UNICEF joint reporting form. Expert Rev Vaccines. 2019;18:859–65. doi:10.1080/14760584.2019.1640119.
   PubMed Web of Science ®Google Scholar
• Koike ME, Gattás VL, Lucchesi MBB, Moura de Oliveira MM, Vanni T, Thomé BDC, Menang O, Socquet M, Precioso AR. Pharmacovigilance capacity strengthening for WHO prequalification: the case of the trivalent influenza vaccine manufactured by Instituto Butantan. Vaccine. 2019;37(52):7560–65. doi:10.1016/j.vaccine.2019.09.082.
   PubMed Web of Science ®Google Scholar
• Gresset-Bourgeois V, Leventhal PS, Pepin S, Hollingsworth R, Kazek-Duret M-P, De Bruijn I, Samson SI. Quadrivalent inactivated influenza vaccine (VaxigripTetra™). Expert Rev Vaccines. 2018;17(1):1–11. doi:10.1080/14760584.2018.1407650.
   PubMed Web of Science ®Google Scholar
• Newman P, Logie C, Lacombe-Duncan A, Baiden P, Tepjan S, Rubincam C, Doukas N, Asey F. Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies. BMJ Open. 2018;8(4):e019206. doi:10.1136/bmjopen-2017-019206.
   PubMed Web of Science ®Google Scholar
• Chan JSK, Harky A. The importance of risk of bias assessment in meta-analyses: does controlling heterogeneity suffice? Eur J Cardio-thoracic Surg. 2020;58(5):1102. doi:10.1093/ejcts/ezaa174.
   PubMed Web of Science ®Google Scholar
• Mondini G, Braga PE, Lopes MH, Sartori AMC, Miyaji KT, Infante V, Randi BA, Timenetsky MDCST, Ferreira JCDOA, Sakita NK, et al. Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan. Rev Inst Med Trop Sao Paulo. 2018;60:e37. doi:10.1590/s1678-9946201860037.
   PubMed Web of Science ®Google Scholar
• Chan YJ, Lee CL, Hwang SJ, Fung CP, Wang FD, Yen DH, Tsai C-H, Chen YMA, Lee S-D. Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan. JCMA. 2010;73(2):62–66. doi:10.1016/S1726-4901(10)70003-4.
   Google Scholar
• Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis. 2013;13:224. doi:10.1186/1471-2334-13-224.
   PubMed Web of Science ®Google Scholar
• Choi WS, Noh JY, Lee J, Choi JY, Lee J-S, Kim MS, Kim HS, Bang J, Lavis N, Kim WJ, et al. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea. Hum Vaccin Immunother. 2018;14(3):587–92. doi:10.1080/21645515.2017.1381808.
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31(5):770–76. doi:10.1016/j.vaccine.2012.11.074.
   PubMed Web of Science ®Google Scholar
• Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC infectious diseases. 2013;13:343.
   Google Scholar
• Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013;31(47):5572–78. doi:10.1016/j.vaccine.2013.08.069.
   PubMed Web of Science ®Google Scholar
• Sesay S, Brzostek J, Meyer I, Donazzolo Y, Leroux-Roels G, Rouzier R, Astruc B, Szymanski H, Toursarkissian N, Vandermeulen C, et al. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: a phase III randomized, double-blind clinical trial. Hum Vaccin Immunother. 2018;14(3):596–608. doi:10.1080/21645515.2017.1384106.
   PubMed Web of Science ®Google Scholar
• Song JY, Lee J, Woo HJ, Wie S-H, Lee JS, Kim SW, Kim TH, Jung S-I, Noh JY, Choi WS, et al. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: a phase randomized clinical trial in adults. Hum Vaccin Immunother. 2019;15(3):710–16. doi:10.1080/21645515.2018.1536589.
   PubMed Web of Science ®Google Scholar
• Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Vaccine. 2014;32(13):1480–87. doi:10.1016/j.vaccine.2014.01.022.
   PubMed Web of Science ®Google Scholar
• Wang SY, Liu SZ, Chu K, Zhao Y, Zhu FC, Hu YM, Meng FY, Li JX, Luo L, Yang JY, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. Expert review of vaccines. 2017;16:1155–69.
   Google Scholar
• Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: a systematic review and meta-analysis of randomised controlled trials. Vaccine. 2016;34(35):4092–102. doi:10.1016/j.vaccine.2016.06.064.
   PubMed Web of Science ®Google Scholar
• Meng Z, Zhang J, Zhang Z, Luo D, Yang X. Immunogenicity of inactivated quadrivalent influenza vaccine in adults aged 18-64 years: a systematic review and meta-analysis. Chin J Epidemiol. 2018;39:1636–41.
   Google Scholar